Last March 31 I published the story of one of the first 45 volunteers who started the trial of the Moderna vaccine we are talking about today.
In a "competition" of effectiveness, immediately after the announcement of Pfizer (which left me very perplexed not by the degree of success, which I cannot verify, but by the difficulties of conservation, which is evident) the announcement of this new Moderna vaccine has arrived.
Modern vaccine: on paper it has many, many more advantages than Pfizer's
The vaccine developed da Moderna bodes well for many other things, not only for the declared effectiveness of 94,5%. It can be a much more distributed and distributable vaccine, because above all it is "cheap". In fact, on the logistical level, the product does not need to be cooled to -80 °. You don't need a whole new cold chain and refrigerators.
And it is not necessary, in the Moderna vaccine, a factor that immediately it had left me very perplexed. The need to transport it in suitcases (32 kilos each) full of dry ice to be continuously re-introduced during the journey, to avoid its deterioration. Only the USA and Canada had the ability to produce all this dry ice in a reasonable time. Well, in the Moderna vaccine you don't need this mountain of dry ice for transport.
This on an economic level translates into tangible differences.
- Cost of a dose of Pfizer vaccine: 16 euros.
- Cost of a dose of AstraZeneca vaccine: 2 euros.
We will see the price of this Moderna vaccine, which at the time I recorded as “the fastest start of a vaccine study ever”. And in any case, before the scientific world reads all the documents produced very carefully, the ones I read are important statements, with a strong economic impact (especially on the stock exchange) and nothing more.
